Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM update

Dr. Goy Discusses Ibrutinib With Venetoclax in MCLПодробнее

Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphomaПодробнее

Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCLПодробнее

Preliminary results of the AIM trial of ibrutinib and venetoclax in mantle cell lymphomaПодробнее

SYMPATICO: ibrutinib combined with venetoclax in patients with R/R MCLПодробнее

Dr. Rule on the Combination of Venetoclax and Ibrutinib in MCLПодробнее

Dr. Ritchie on the Immunologic Impact of Long-Term Venetoclax/Ibrutinib in R/R MCLПодробнее

Dr. Ritchie on Immunological Response to Venetoclax/Ibrutinib in R/R MCLПодробнее

SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCLПодробнее

Dr. Tam on the Toxicity of Ibrutinib Plus Venetoclax in MCLПодробнее

ASH23: Ibrutinib Combined with Venetoclax in Patients with RR Mantle Cell Lymphoma: Primary Anal...Подробнее

Venetoclax Plus Ibrutinib Combo Shows Potential in Relapsed/Refractory MCLПодробнее

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCLПодробнее

The role of venetoclax in R/R MCL & options for patients who progress on venetoclaxПодробнее

Dr. Tam on the Combination of Ibrutinib Plus Venetoclax in Mantle Cell LymphomaПодробнее

Assoc. Prof. Constantine Tam: Ibrutinib + Venetoclax in R/R MCL - ICML 2017Подробнее

OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCLПодробнее

Ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed MCLПодробнее

Copy of Dr. Kaplan on the Combination of Ibrutinib and Venetoclax in MCLПодробнее